CureVac NV
5CV
Company Profile
Business description
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Contact
Friedrich-Miescher-Strasse 15
TubingenBW72076
DEUT: +49 707198830
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,088
Stocks News & Analysis
stocks
Has the most hated company on the ASX 200 bounced back?
Encouraging results indicate a potential turnaround story.
stocks
Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown
We think Amazon stock looks attractive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,922.00 | 4.90 | 0.05% |
| CAC 40 | 7,632.01 | 85.85 | 1.14% |
| DAX 40 | 23,757.69 | 331.72 | 1.42% |
| Dow JONES (US) | 44,144.62 | 556.04 | 1.28% |
| FTSE 100 | 9,128.30 | 59.72 | 0.66% |
| HKSE | 24,733.45 | 225.64 | 0.92% |
| NASDAQ | 21,007.35 | 357.21 | 1.73% |
| Nikkei 225 | 40,290.70 | 508.90 | -1.25% |
| NZX 50 Index | 12,684.04 | 45.36 | -0.36% |
| S&P 500 | 6,320.93 | 82.92 | 1.33% |
| S&P/ASX 200 | 8,663.70 | 1.70 | 0.02% |
| SSE Composite Index | 3,583.31 | 23.36 | 0.66% |